Lepu Medical Technology (Beijing) Co. Bundle
Who owns Lepu Medical Technology (Beijing) Co. Company?
Understanding Lepu Medical Technology's ownership is key to its strategy and governance. Its listing on the Shenzhen Stock Exchange in 2009 and GDRs on the SIX Swiss Exchange in 2022 broadened its investor base.
Founded in 1999, Lepu Medical Technology (Beijing) Co., Ltd. is a major medical device company focused on cardiovascular interventions. As of August 19, 2025, its market capitalization stood at approximately $4.73 billion, with 1.88 billion shares outstanding.
The ownership structure of Lepu Medical Technology (Beijing) Co., Ltd. is a blend of founder stakes, institutional investors, and public shareholders. This dynamic ownership influences its strategic decisions and market position. For instance, its development of products like the Lepu Medical Technology (Beijing) Co. PESTEL Analysis reflects its commitment to innovation and market expansion.
Who Founded Lepu Medical Technology (Beijing) Co.?
Lepu Medical Technology (Beijing) Co., Ltd. was established in 1999, with Dr. Pu Zhongjie recognized as a principal founder and the company's legal representative. He also holds the position of controlling shareholder and actual controller for both Lepu Medical Technology and its affiliate, Lepu Biopharma Co., Ltd..
| Founder | Role | Ownership Status |
|---|---|---|
| Dr. Pu Zhongjie | Founder, Legal Representative, Controlling Shareholder, Actual Controller | Primary |
Founding Year
The company was founded in 1999, marking the beginning of its journey in the medical technology sector.
Key Founder
Dr. Pu Zhongjie is identified as a key founder and the legal representative, playing a pivotal role from the outset.
Controlling Shareholder
Dr. Pu Zhongjie is recognized as the controlling shareholder and actual controller, indicating significant influence over the company's direction.
Affiliated Company Control
This control extends to Lepu Biopharma Co., Ltd., a subsidiary, highlighting a consolidated ownership structure.
Early Ownership Details
Specifics on the initial equity distribution among founders are not publicly detailed, but Dr. Pu Zhongjie's ongoing role suggests a founder-centric initial ownership.
Initial Backer Information
There is no public information detailing early backers, angel investors, or friends and family investments during the initial phase.
The founding team's strategic vision was to establish a comprehensive provider of cardiovascular disease solutions, with the distribution of control firmly centered around Dr. Pu Zhongjie's leadership. This foundational structure has guided the company's development and its approach to the market, as further explored in the Target Market of Lepu Medical Technology (Beijing) Co..
Founding Vision
The company was built with a clear objective to offer complete solutions for cardiovascular diseases.
- Founder-led vision
- Focus on cardiovascular solutions
- Consolidated control structure
- Strategic early direction
Lepu Medical Technology (Beijing) Co. SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Lepu Medical Technology (Beijing) Co.’s Ownership Changed Over Time?
Lepu Medical Technology (Beijing) Co.'s ownership journey significantly shifted with its 2009 Shenzhen Stock Exchange IPO and subsequent 2022 Swiss Exchange GDR listing, broadening its investor base and capital access. These events were pivotal in shaping its current stakeholder landscape.
| Shareholder | Percentage of Ownership | Number of Shares |
|---|---|---|
| Dr. Pu Zhongjie | 9.951% | 160,618,687 |
| Hwabao WP Fund Management Co., Ltd. | 2.664% | 42,996,418 |
| WP Medical Technologies, Inc. | 1.92% | 30,992,150 |
| Ningbo Houde Yimin Investment Management Co., Ltd. | 1.94% | 35,850,000 |
| Norges Bank Investment Management | 1.67% | 30,762,145 |
| China Southern Asset Management Co., Ltd. | 1.27% | 20,502,734 |
The ownership structure of Lepu Medical Technology (Beijing) Co. reflects a blend of founder-led influence and growing institutional investment. As of December 31, 2024, with a total of 1,880,611,005 shares, Dr. Pu Zhongjie remains the largest individual shareholder. The company's strategic expansion into international capital markets, notably through its 2022 GDR listing which raised approximately USD 224 million, has attracted significant institutional players. These include entities like Hwabao WP Fund Management Co., Ltd., WP Medical Technologies, Inc., Ningbo Houde Yimin Investment Management Co., Ltd., Norges Bank Investment Management, and China Southern Asset Management Co., Ltd., all holding substantial stakes. This diverse shareholder base underscores the company's evolution and its commitment to global growth and innovation, as detailed in its Revenue Streams & Business Model of Lepu Medical Technology (Beijing) Co..
Key Stakeholders in Lepu Medical Technology
Understanding who owns Lepu Medical Technology (Beijing) Co. is crucial for assessing its strategic direction and corporate governance.
- Founder Dr. Pu Zhongjie is the largest individual shareholder.
- Significant institutional investors include Hwabao WP Fund Management and Norges Bank Investment Management.
- The company's public listing on the Shenzhen Stock Exchange in 2009 was a major ownership milestone.
- A 2022 GDR listing on the SIX Swiss Exchange further diversified its ownership.
- As of December 31, 2024, the total share capital stood at 1,880,611,005 shares.
Lepu Medical Technology (Beijing) Co. PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Lepu Medical Technology (Beijing) Co.’s Board?
The board of directors for Lepu Medical Technology (Beijing) Co., Ltd. is currently led by Dr. Pu Zhongjie, who holds the positions of legal representative, Chairman of the Board, and Head of Technology. Ms. Wang Yong serves as the financial director and is in charge of accounting work, supported by Ms. Li Yun as the head of the accounting department. This structure highlights key financial and technological leadership within the company.
| Director Name | Role | Key Responsibilities |
|---|---|---|
| Dr. Pu Zhongjie | Chairman of the Board, Legal Representative, Head of Technology | Overall company leadership, technological direction, legal compliance |
| Ms. Wang Yong | Financial Director, Person in Charge of Accounting Work | Financial management, accounting oversight |
| Ms. Li Yun | Head of the Accounting Department | Day-to-day accounting operations |
Dr. Pu Zhongjie's role as the legal representative and controlling shareholder significantly influences the company's voting power. The 2024 Annual Report confirms that the company is 'Controlled by a natural person,' which is Dr. Pu Zhongjie, indicating his substantial control over the organization. While specific details on other board members and their voting percentages are not provided, his status as the controlling shareholder suggests he holds the majority of the voting power. There have been no publicly disclosed proxy battles or activist investor campaigns targeting Lepu Medical Technology (Beijing) Co., Ltd. recently, though governance changes were noted for a related entity, LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., in July 2024.
Understanding Lepu Medical Beijing's Governance
The ownership structure of Lepu Medical Beijing is primarily controlled by a single individual, Dr. Pu Zhongjie. This natural person control is a key aspect of the company's corporate governance.
- Dr. Pu Zhongjie is the controlling shareholder.
- He serves as Chairman and legal representative.
- Financial oversight is managed by Ms. Wang Yong.
- The company's control is not through dual-class shares.
- Recent governance changes were observed in a related entity.
Lepu Medical Technology (Beijing) Co. Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Lepu Medical Technology (Beijing) Co.’s Ownership Landscape?
Recent developments in Lepu Medical Technology (Beijing) Co. reflect a dynamic ownership landscape, influenced by strategic financial maneuvers and evolving market conditions. The company has actively managed its share capital and expanded its operational reach through key acquisitions and licensing agreements.
| Development | Date | Details |
| Equity Buyback | October 2023 | Repurchased 18,942,200 shares for CNY 252.65 million (1.02% of total share capital) |
| Subsidiary Acquisitions | November 2024 | Lepu Growth acquired stakes in Ningbo Xiran (12.44%), Ningbo Langhui (37.74%), Ningbo Langwan (14.71%), and Ningbo Langxin (11.01%) |
| Licensing Agreement | January 2025 | Lepu Biopharma licensed an ADC to ArriVent BioPharma for $47 million upfront and up to $1.16 billion in milestones |
| Financial Performance | 2024 & Q1 2025 | Operating revenue decreased by 23.52% in 2024 to RMB 6,103.2691 million and by 9.67% in Q1 2025 to RMB 1,736.2313 million; net profit also reduced. |
| Dividend Approval | April 2025 | Approved a 2024 cash dividend of RMB 1.3500 per 10 shares, payable in June 2025 |
These actions suggest a strategic approach to managing shareholder value and expanding the company's market presence, particularly in international markets and emerging sectors like Brain-computer Interfaces. The financial performance data indicates a period of adjustment, potentially leading to further restructuring and shifts in stakeholder interests.
Share Repurchase Strategy
The company's equity buyback in October 2023 signals a commitment to enhancing shareholder value. This move can also indicate confidence in the company's intrinsic worth and future prospects.
Strategic Expansion Through Acquisitions
In November 2024, a subsidiary's acquisitions broadened its investment portfolio. These strategic moves aim to diversify revenue streams and strengthen market position within specific sectors.
Collaborative Growth and Licensing
The January 2025 licensing agreement highlights a trend towards external collaborations for product development. Such partnerships are crucial for accessing new technologies and markets, as seen with the experimental antibody-drug conjugate.
Financial Adjustments and Future Focus
Despite revenue declines in 2024 and early 2025, the company is prioritizing overseas business development for GLP-1 drugs and advancing its Brain-computer Interface sector. These strategic directions are key to navigating current financial performance and shaping future ownership trends. Understanding these shifts is vital for grasping the Mission, Vision & Core Values of Lepu Medical Technology (Beijing) Co.
Lepu Medical Technology (Beijing) Co. Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Lepu Medical Technology (Beijing) Co. Company?
- What is Competitive Landscape of Lepu Medical Technology (Beijing) Co. Company?
- What is Growth Strategy and Future Prospects of Lepu Medical Technology (Beijing) Co. Company?
- How Does Lepu Medical Technology (Beijing) Co. Company Work?
- What is Sales and Marketing Strategy of Lepu Medical Technology (Beijing) Co. Company?
- What are Mission Vision & Core Values of Lepu Medical Technology (Beijing) Co. Company?
- What is Customer Demographics and Target Market of Lepu Medical Technology (Beijing) Co. Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.